Table 1.
COVID-19 conventional therapeutics.
| Therapeutics | Name | Target/rational for use | Clinical phase | status | Findings |
|---|---|---|---|---|---|
| Drugs | Remdesivir | an inhibitor of RNA-dependent RNA polymerase (RdRP) | Phase III | Ongoing | No Result Posted |
| Dexamethasone | Inhibition of Strongyloides hyperinfection syndrome | Phase IV | Recruiting | No Result Posted | |
| Hydroxychloroquine | Block viral entry by inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification. | Phase III | Completed | No Result Posted | |
| Vaccines | mRNA-1273 | S protein | Phase III | Recruiting | No Result Posted |
| AZD-1222 | S protein | Phase III | Recruiting | No Result Posted | |
| Ad5- nCoV | S protein | Phase III | Recruiting | No Result Posted | |
| Antibodies | LY-CoV555 | S protein | Phase III | Recruiting | No Result Posted |
| REGN-COV-2 | S protein | Phase III | Recruiting | No Result Posted |